{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DNA",
  "name": "Ginkgo Bioworks Holdings, Inc.",
  "url": "https://frontierpicks.com/dossiers/DNA/",
  "json_url": "https://frontierpicks.com/dossiers/DNA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "Ginkgo Bioworks' shares have recovered to $11.21 (30 October 2026 close) from the $10.07 October low, yet second-quarter revenue fell 48%. The company-confirmed third-quarter report on 5 November 2026 shows whether Datapoints and autonomous-lab sales can turn revenue up.",
  "invalidation_trigger": "A daily close below $9.76, the 2026-10-19 intraday low, which would extend the full reversal of the October rally. Third-quarter revenue below the second quarter's $20.2 million, with no Datapoints or lab growth named, would break the case on business grounds.",
  "catalyst_date": "2026-11-05",
  "pick": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Ginkgo carried out a 1-for-40 reverse stock split in 2024; earlier per-share prices are comparable only on split-adjusted charts.",
    "Ginkgo has a dual-class share structure: Class B shares held by founders and insiders carry multiple votes per share, concentrating voting control.",
    "The company reports as a single segment since divesting its biosecurity business, so Datapoints and autonomous-lab revenue are not broken out separately."
  ],
  "source_links": [],
  "body_markdown": "## Current Thesis\n\nGinkgo Bioworks' shares have recovered to $11.21 (close, 2026-10-30) from the $10.07 close of 2026-10-19, but the business behind them is still shrinking: second-quarter revenue fell 48% to $20.2 million. The third-quarter report on 2026-11-05, which the company confirmed on 2026-10-30, shows whether Datapoints and autonomous-lab sales can turn revenue back up.\n\nThe case is that Ginkgo is turning its robotic lab capacity into two products. It sells data generated on its own automated lines (Datapoints), and it builds and rents autonomous labs. The Eli Lilly TuneLab agreement of 2026-09-16 (Benzinga) gave that story a named pharmaceutical customer. NSF X-Labs and Araceli Biosciences announcements followed on 2026-10-08.\n\nThe price has moved faster than the filings. The shares closed at a 52-week high of $14.98 on 2026-10-05, the day call-option volume rose 898% (GuruFocus). The latest close sits 25.2% below that high and 19.6% above the close three months earlier. The narrative is maturing: the 2026-10-08 announcements produced only a one-day lift on 2026-10-09 (Benzinga), and no new commercial announcement has appeared since. The coming report is the first hard revenue test of the Lilly deal.\n\n## Bull Case\n\n- **A pharma major is a named customer.** The Lilly TuneLab agreement covers small-molecule and antibody developability testing through Ginkgo Datapoints (Benzinga, 2026-09-16).\n- **The lab network keeps adding pieces.** On 2026-10-08 Ginkgo said it will give National Science Foundation (NSF) X-Labs researchers autonomous-lab access. The same day it integrated Araceli Biosciences' Endeavor imaging instrument into Nebula, its Boston autonomous lab.\n- **Autonomous-lab contracts are signed orders.** The 2026-08-05 second-quarter release cites NSF-funded labs at MIT, Caltech, Northwestern and the University of Maryland, plus a $47 million, 97-instrument lab for the EMSL facility at Pacific Northwest National Laboratory.\n- Management reaffirmed 2026 cash burn guidance of $125 million to $150 million (Q2 2026 release, 2026-08-05).\n- **The shares are holding above the October low.** The close of $11.21 on 2026-10-30 is above the $10.07 close of 2026-10-19 and above TD Cowen's $11 price target (raised from $9 on 2026-10-13).\n\n## Bear Case\n\n- **Revenue is shrinking.** Second-quarter 2026 revenue was $20.2 million, against $39.1 million a year earlier. The company attributes the decline to program cuts under its restructuring (Q2 2026 release, 2026-08-05).\n- **Losses are not narrowing yet.** The second-quarter net loss from continuing operations was $57.3 million. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was negative $36.3 million, worse than negative $25 million a year earlier (Q2 2026 release, 2026-08-05).\n- **The new lab deals carry no disclosed revenue.** The NSF X-Labs contribution is in-kind lab time, and Ginkgo has not said whether it will generate sales. Management gave no 2026 revenue outlook on 2026-08-05.\n- **Analysts still sit below the price.** StockAnalysis showed three analysts with a Sell consensus and an average 12-month target of $8.00 on 2026-10-19. BTIG reiterated Sell with a $5 target on 2026-09-04.\n- **Insider selling came at the peak.** A Form 4 shows the chief financial officer sold 2,403 shares at $15 under a Rule 10b5-1 plan, in the 2026-10-05 spike.\n\n## Setup & Price Structure\n\nThe last completed daily close is $11.21 (2026-10-30). The 52-week high is $14.98, set on 2026-10-05. The 14-day relative strength index (RSI) reads 46.6, neither stretched nor oversold.\n\nThe October range is wide. The shares traded between $12.32 and $15.48 on the spike day, then reached an intraday low of $9.76 on 2026-10-19. That low is the level that would mark a full reversal of the rally.\n\nCrowding evidence is mixed. The 898% jump in call-option volume on 2026-10-05 and the same-day insider sale showed heavy speculative attention near the high. Attention has since faded, but the report is four sessions away, and the shares have a record of large post-earnings moves; one third-party analysis puts the average absolute next-day move at 13.45%.\n\n## Catalyst Calendar (next 30 days)\n\n*No upcoming dated catalysts on file — the dated entries below have passed.*\n\n## Elapsed catalysts\n\n- **2026-11-05: Third-quarter 2026 results.** The company announced on 2026-10-30 that it will review performance on this date. It is the first report covering the Lilly agreement and shows whether revenue has stopped falling from $20.2 million. *(passed 1d ago)*\n- **~2026-11-05 (est.): Form 10-Q.** It would show cash at 2026-09-30, any at-the-market share sales, and any revenue detail on the lab arrangements. *(passed 1d ago)*\n\n## What Would Change Our Mind\n\nThe case breaks if third-quarter revenue comes in below the second quarter's $20.2 million with no growth named in Datapoints or autonomous labs. It also breaks if the 10-Q shows new share issuance to fund losses, or if cash burn runs above the $125 million to $150 million guidance range.\n\nOn price, a daily close below $9.76, the 2026-10-19 intraday low, would extend the reversal of the October rally. A report showing higher revenue with Datapoints or lab sales named as the cause would strengthen the case. Even then, the 2026-10-05 high of $14.98 and the Sell-leaning analyst average of $8.00 frame how far the market has already credited the story.\n\n## Correlation Notes\n\nGinkgo trades on its own news flow more than on a sector driver. Its October spike came on a company announcement and a surge in options activity, and it coincided with double-digit gains in other small biotech and life-science tools names on 2026-10-06 (Benzinga). Its direction around 2026-11-05 depends mainly on the company's own revenue and cash figures.",
  "first_seen": "2026-10-05",
  "last_analyzed": "2026-11-02T05:18:30+00:00",
  "last_synthesized": "2026-11-02",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}